GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 77
- Registration Number
- NCT00920257
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT00920140
- Locations
- 🇩🇪
GSK Investigational Site, Leipzig, Sachsen, Germany
A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults
- Conditions
- Influenza
- Interventions
- Biological: Fluarix™/Influsplit SSW®
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 118
- Registration Number
- NCT00920374
- Locations
- 🇩🇪
GSK Investigational Site, Freital, Sachsen, Germany
Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT00920192
- Locations
- 🇹🇭
GSK Investigational Site, Khon Kaen, Thailand
DDI Study of Etravirine and GSK1265744
- Conditions
- Healthy SubjectsInfection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00920296
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs
- Conditions
- Healthy SubjectsInfection, Human Immunodeficiency Virus
- Interventions
- Drug: darunavir/ritonavir
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2010-11-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00920088
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers
- Conditions
- Poliomyelitis
- Interventions
- Biological: PoliorixTM
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT00920439
- Locations
- 🇨🇳
GSK Investigational Site, Wuzhou, Guangxi, China
Advair Pediatric Once-Daily
- Conditions
- Asthma
- Interventions
- Drug: FSC 100/50mcgDrug: FP 100mcgDrug: Placebo
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 908
- Registration Number
- NCT00920959
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
- Conditions
- Herpes Zoster
- Interventions
- Biological: Placebo vaccine (saline)Biological: Herpes Zoster Vaccine 1437173A
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 121
- Registration Number
- NCT00920218
- Locations
- 🇺🇸
GSK Investigational Site, Philadelphia, Pennsylvania, United States
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
- Conditions
- Thrombosis, Venous
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 39
- Registration Number
- NCT00911157
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan